Nephros Inc

Análisis de la acción Nephros Inc (NEPH)

$2.833

-0.236 (-8.32%)Al cierre

Loading chart…
Máximo
3.080
Apertura
3.080
Precio medio ponderado por volumen
2.88
Volumen
104.01K
Capitalización
22.04M
Mínimo
2.720
Importe
299.30K
EV/EBITDA, TTM
5.64

Nephros, Inc. is a water technology company providing filtration solutions to the medical and commercial markets. The Company provides water filtration products and services, along with water-quality education. In the medical markets, it sells water filtration products. In the commercial market, it manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, heavy metals, chemical compounds, scale build-up in downstream equipment, and various other contaminants. Its products are marketed primarily to the food service, hospitality, convenience store, and healthcare markets. These commercial products are also marketed in medical markets as supplemental filtration to its medical filters. Its filters are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate.

www.nephros.com

Análisis de IA of Nephros Inc (NEPH)

Mantener

Nephros Inc is currently not a strong buy due to its low RSI of 16.83, indicating oversold conditions, and a significant 40.36% year-to-date decline. While the company reported record revenue of $6 million in Q2 2026 and a net income increase of over 400% to approximately $1.2 million, the stock's recent performance has been poor, with a 10.63% drop over the last five days. The main risk is its high debt to equity ratio of 6.17%, which could impact financial stability.

Métricas de valoración

El PER previsto actual de Nephros Inc (NEPH) es 0.00, frente a su media de 5 años de -23.55.

PER previsto

Valor razonable
Media 5A P/E
-23.55
P/E actual
0.00
Sobrevalorada
118.86
Infravalorada
-165.96

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
3.79
EV/EBITDA actual
5.64
Sobrevalorada
28.55
Infravalorada
-20.97

Precio/ventas previsto

Valor razonable
Media 5A P/S
1.85
P/S actual
1.31
Sobrevalorada
3.01
Infravalorada
0.69

Escenarios de precio de Alphio AI para NEPH

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%NEPH

$3.45

Precio del escenario

B

Base

Base · 50%NEPH

$2.82

Precio del escenario

B

Bajista

Bajista · 25%NEPH

$2.02

Precio del escenario

Cronología de eventos

2026-08-06 (ET)

18:00:00

Nephros Reports Q2 Revenue of $6.02M

2026-02-13 (ET)

08:20:00

Nephros Enters Puerto Rican Market to Address Water Quality Needs

2025-12-11 (ET)

09:10:00

Nephros Launches Water Institute to Enhance Industry Education

2025-10-08 (ET)

09:11:53

Nephros Introduces New Filter for PFAS Removal

2024-10-24 (ET)

09:09:57

Nephros launches HydraGuard 20" UltraFilter

Noticias

Preguntas frecuentes sobre NEPH, respondidas por Alphio AI

Nephros, Inc. is a water technology company providing filtration solutions to the medical and commercial markets. The Company provides water filtration products and services, along with water-quality education. In the medical markets, it sells water filtration products. In the commercial market, it manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, heavy metals, chemical compounds, scale build-up in downstream equipment, and various other contaminants. Its products are marketed primarily to the food service, hospitality, convenience store, and healthcare markets. These commercial products are also marketed in medical markets as supplemental filtration to its medical filters. Its filters are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. It operates in the Industrials sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Nephros Inc is currently not a strong buy due to its low RSI of 16.83, indicating oversold conditions, and a significant 40.36% year-to-date decline. While the company reported record revenue of $6 million in Q2 2026 and a net income increase of over 400% to approximately $1.2 million, the stock's recent performance has been poor, with a 10.63% drop over the last five days. The main risk is its high debt to equity ratio of 6.17%, which could impact financial stability.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar